Trial Profile
A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Volrustomig (Primary) ; Carboplatin; Pembrolizumab; Pemetrexed
- Indications Head and neck cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors AstraZeneca; MedImmune
- 12 Mar 2024 Planned End Date changed from 29 Apr 2025 to 30 Apr 2025.
- 12 Mar 2024 Planned primary completion date changed from 29 Apr 2025 to 30 Apr 2025.
- 12 Mar 2024 Status changed from recruiting to active, no longer recruiting.